Marc Machaalani
Hospital ResidentCards
About
Research
Publications
2026
Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma
Dudipala H, Dugan A, Jariwala U, Ronski K, Mercer J, Saad E, Masri J, Machaalani M, Saleh M, Layng K, Yu Y, Signoretti S, Braun D, Pal S, Choueiri T, McKay R. Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma. The Oncologist 2026, 31: oyag317. PMID: 42578740, PMCID: PMC13537524, DOI: 10.1093/oncolo/oyag317.Peer-Reviewed Original ResearchMetabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
Suissa D, Fidelle M, Reich E, Pham T, Thomas S, Björk J, Liu P, Zhao L, Kitaoka K, Piard E, Lebhar I, Tian A, Thelemaque C, Alves Costa Silva C, Deutsch E, Loriot Y, Segata N, Piccinno G, Hospers G, Maleki Vareki S, Silverman M, Lenehan J, Bataille V, Boulate D, Kuznetsova T, Weersma R, Messaoudene M, Durand S, van der Aalst C, de Koning H, Schuler-Thurner B, de Vries I, Rafie E, Saliby R, Machaalani M, Haferkamp S, Schilling B, Porcari S, Ciccarese C, Iacovelli R, Cremolini C, Choueiri T, Elkrief A, Kroemer G, Heinzerling L, Chamoto K, Ianiro G, Routy B, Derosa L, Paragios N, Zitvogel L. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. Nature Medicine 2026, 32: 2918-2932. PMID: 42350644, PMCID: PMC13472865, DOI: 10.1038/s41591-026-04481-9.Peer-Reviewed Original ResearchThe clinical landscape of HIF2α inhibitors in oncology
Saad E, Machaalani M, McDermott D, Choueiri T. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology 2026, 23: 501-519. PMID: 42050152, DOI: 10.1038/s41571-026-01145-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPublisher Correction: argeting of HIF2-driven cachexia in kidney cancer
Abu-Remaileh M, Stransky L, Bhalerao N, Shirole N, Jiang Q, Saad E, Machaalani M, Vigeant S, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri T, Pitarresi J, Carr S, Udeshi N, Kaelin W. Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer. Nature Medicine 2026, 32: 766-766. PMID: 41606123, PMCID: PMC12920078, DOI: 10.1038/s41591-026-04236-6.Commentaries, Editorials and LettersIntegrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Yekedüz E, Bian W, Siegmund S, Machaalani M, Masri J, Saleh M, Saad E, Ascione L, Chehade R, Steiner C, Barrios P, Berg S, McGregor B, Mantia C, Ravi P, Xu W, Hirsch M, Choueiri T, Serzan M. Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2. Clinical Cancer Research 2026, 32: 1169-1179. PMID: 41524698, PMCID: PMC12924687, DOI: 10.1158/1078-0432.ccr-25-2871.Peer-Reviewed Original ResearchSoluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Alves Costa Silva C, Machaalani M, Saliby R, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, Vernerey D, Lee G, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Choueiri T, Albiges L. Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma. Nature Medicine 2026, 32: 671-681. PMID: 41501493, PMCID: PMC12920104, DOI: 10.1038/s41591-025-04067-x.Peer-Reviewed Original ResearchChapter 4 Stem cell-mediated alleviation of pyroptosis in cerebral injuries
Masri J, Masri D, Saleh M, Al Chaar S, Machaalani M, Bahmad H, Abou-Kheir W. Chapter 4 Stem cell-mediated alleviation of pyroptosis in cerebral injuries. 2026, 111-130. DOI: 10.1016/b978-0-443-40471-9.00004-5.Chapters
2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
Nassar A, Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri T, Rakaee M, Busund L, Takabe Y, Lau S, Rall K, Naqash A, Jansen C, Wang X, Challa P, Tarantino P, Partridge A, Tolaney S, Kwiatkowski D, Winer E. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. Journal Of The National Cancer Institute 2025, 118: 669-679. PMID: 41418409, DOI: 10.1093/jnci/djaf344.Peer-Reviewed Original ResearchTargeting of HIF2-driven cachexia in kidney cancer
Abu-Remaileh M, Stransky L, Bhalerao N, Shirole N, Jiang Q, Saad E, Machaalani M, Vigeant S, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri T, Pitarresi J, Carr S, Udeshi N, Kaelin W. Targeting of HIF2-driven cachexia in kidney cancer. Nature Medicine 2025, 32: 245-257. PMID: 41315757, PMCID: PMC12823431, DOI: 10.1038/s41591-025-04054-2.Peer-Reviewed Original ResearchThe SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Grubb T, Koochaki P, Matar S, Ghandour F, Machaalani M, Saad E, Tang C, Reznik E, Khatun J, Salem C, Dubasik N, Orlando D, Guenther M, Parajuli G, Srivastava R, Martinez S, Coker J, Kotecha R, Hakimi A, Asara J, Chan T, Vanharanta S, Stauffer S, Kaelin W, Signoretti S, Choueiri T, Chakraborty A. The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs. Nature Communications 2025, 16: 10012. PMID: 41238532, PMCID: PMC12618888, DOI: 10.1038/s41467-025-64983-x.Peer-Reviewed Original Research